Cronos (CRON) Cash from Investing Activities (2019 - 2026)
Cronos' (CRON) quarterly Cash from Investing Activities came in at $38.0 million in Q1 2026, up 168.7% year-on-year from $14.2 million in Q1 2025, and up 1266.97% quarter-over-quarter from $2.8 million in Q4 2025.
Cronos (CRON) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Cronos' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $38.0 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 168.7% year-over-year to $38.0 million in Q1 2026; TTM through Mar 2026 was $16.8 million, a 124.12% increase from a year earlier, with the FY2025 full-year figure at -$76.6 million, down 143.71% from the prior year.
- Cash from Investing Activities rose to $38.0 million in Q1 2026 per CRON's latest filing, from $2.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $189.6 million in Q1 2024 and bottomed at -$303.8 million in Q1 2023.
- The 5-year median for Cash from Investing Activities is -$818000.0 (2024), against an average of $4.4 million.
- Biggest YoY gain for Cash from Investing Activities was 231.33% in 2023; the steepest drop was 303912.0% in 2023.
- Year by year, Cash from Investing Activities stood at $158.5 million in 2022, then slumped by 48.32% to $81.9 million in 2023, then tumbled by 106.14% to -$5.0 million in 2024, then soared by 155.29% to $2.8 million in 2025, then surged by 1266.97% to $38.0 million in 2026.
- Per Business Quant, the three latest CRON Cash from Investing Activities figures stand at $38.0 million (Q1 2026), $2.8 million (Q4 2025), and -$23.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Cronos | 1.06 Bn | 240.39 Mn | 19.15 Mn | 38.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.03 Mn |
| Mar 31, 2026 | 38.03 Mn |
| Dec 31, 2025 | 2.78 Mn |
| Dec 31, 2025 | 2.78 Mn |
| Sep 30, 2025 | -23.00 Mn |
| Sep 30, 2025 | -23.00 Mn |
| Jun 30, 2025 | -983,000.00 |
| Jun 30, 2025 | -983,000.00 |
| Mar 31, 2025 | -55.36 Mn |
| Mar 31, 2025 | -55.36 Mn |
| Dec 31, 2024 | -5.03 Mn |
| Dec 31, 2024 | -5.03 Mn |
| Sep 30, 2024 | -818,000.00 |
| Sep 30, 2024 | -818,000.00 |
| Jun 30, 2024 | -8.56 Mn |
| Jun 30, 2024 | -8.56 Mn |
| Mar 31, 2024 | 189.56 Mn |
| Mar 31, 2024 | 189.56 Mn |
| Dec 31, 2023 | 81.89 Mn |
| Dec 31, 2023 | 81.89 Mn |